Atezolizumab (Tecentriq) Receives FDA Approval for Extensive-Stage Small Cell Lung Cancer
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The LungCancer.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer. United States Food and Drug Administration. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633814.htm. Published March 18, 2019. Accessed March 21, 2019.
- FDA Approves Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer. Genentech. https://www.gene.com/media/press-releases/14783/2019-03-18/fda-approves-genentechs-tecentriq-in-com. Published March 18, 2019. Accessed March 21, 2019.
- Mulcahy N. FDA Approves Atezolizumab for Small Cell Lung Cancer. Medscape. https://www.medscape.com/viewarticle/910595. Published March 19, 2019. Accessed March 21, 2019.
- Horn L, Mansfield AS, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. The New England Journal of Medicine. 6 Dec 2018; 379, 2220-9.